Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report published on Thursday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

BTX opened at $0.84 on Thursday. The company has a market capitalization of $49.12 million, a P/E ratio of -0.37 and a beta of 4.61. The company has a 50-day moving average of $1.17 and a 200-day moving average of $1.62. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.